A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2018
At a glance
- Drugs CBLC 137 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Cleveland BioLabs; Incuron
- 29 Mar 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 29 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2019.
- 17 Jan 2017 Status changed from not yet recruiting to recruiting.